JP2014530226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530226A5 JP2014530226A5 JP2014535044A JP2014535044A JP2014530226A5 JP 2014530226 A5 JP2014530226 A5 JP 2014530226A5 JP 2014535044 A JP2014535044 A JP 2014535044A JP 2014535044 A JP2014535044 A JP 2014535044A JP 2014530226 A5 JP2014530226 A5 JP 2014530226A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- antibody
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000005557 antagonist Substances 0.000 claims 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 6
- 229960000485 methotrexate Drugs 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 3
- 229960004171 hydroxychloroquine Drugs 0.000 claims 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 3
- 229960000681 leflunomide Drugs 0.000 claims 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 3
- 229960001940 sulfasalazine Drugs 0.000 claims 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229960003115 certolizumab pegol Drugs 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 102000052611 human IL6 Human genes 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545864P | 2011-10-11 | 2011-10-11 | |
| US61/545,864 | 2011-10-11 | ||
| EP12305889 | 2012-07-20 | ||
| EP12305889.3 | 2012-07-20 | ||
| PCT/EP2012/070052 WO2013053751A1 (en) | 2011-10-11 | 2012-10-10 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064130A Division JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530226A JP2014530226A (ja) | 2014-11-17 |
| JP2014530226A5 true JP2014530226A5 (OSRAM) | 2015-12-03 |
| JP6122018B2 JP6122018B2 (ja) | 2017-04-26 |
Family
ID=48081395
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535044A Active JP6122018B2 (ja) | 2011-10-11 | 2012-10-10 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2017064130A Active JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2018086193A Active JP6983717B2 (ja) | 2011-10-11 | 2018-04-27 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2020088567A Active JP7025477B2 (ja) | 2011-10-11 | 2020-05-21 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2024039618A Pending JP2024069453A (ja) | 2011-10-11 | 2024-03-14 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064130A Active JP6336171B2 (ja) | 2011-10-11 | 2017-03-29 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2018086193A Active JP6983717B2 (ja) | 2011-10-11 | 2018-04-27 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2020088567A Active JP7025477B2 (ja) | 2011-10-11 | 2020-05-21 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
| JP2024039618A Pending JP2024069453A (ja) | 2011-10-11 | 2024-03-14 | 関節リウマチを治療するための組成物およびこれを用いる方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10927435B2 (OSRAM) |
| EP (1) | EP2766039B1 (OSRAM) |
| JP (5) | JP6122018B2 (OSRAM) |
| KR (3) | KR20220035272A (OSRAM) |
| CN (2) | CN104105505A (OSRAM) |
| AR (1) | AR088289A1 (OSRAM) |
| AU (1) | AU2012323062B2 (OSRAM) |
| BR (1) | BR112014008764A8 (OSRAM) |
| CA (1) | CA2851751A1 (OSRAM) |
| CL (1) | CL2014000926A1 (OSRAM) |
| CO (1) | CO6950482A2 (OSRAM) |
| DK (1) | DK2766039T3 (OSRAM) |
| ES (1) | ES2660112T3 (OSRAM) |
| HU (1) | HUE036561T2 (OSRAM) |
| IL (1) | IL232001A0 (OSRAM) |
| LT (1) | LT2766039T (OSRAM) |
| MA (1) | MA35620B1 (OSRAM) |
| MX (3) | MX388710B (OSRAM) |
| MY (1) | MY177212A (OSRAM) |
| NO (1) | NO2766039T3 (OSRAM) |
| PH (1) | PH12014500784B1 (OSRAM) |
| PL (1) | PL2766039T3 (OSRAM) |
| PT (1) | PT2766039T (OSRAM) |
| RS (1) | RS56973B1 (OSRAM) |
| RU (1) | RU2664697C2 (OSRAM) |
| SG (3) | SG10201607215SA (OSRAM) |
| SI (1) | SI2766039T1 (OSRAM) |
| TR (1) | TR201802387T4 (OSRAM) |
| TW (1) | TWI589299B (OSRAM) |
| UY (1) | UY34387A (OSRAM) |
| WO (1) | WO2013053751A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| CN110711248A (zh) | 2011-01-28 | 2020-01-21 | 赛诺菲生物技术公司 | 包含针对pcsk9的人抗体的药物组合物 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| WO2014096464A1 (de) * | 2013-01-31 | 2014-06-26 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmazeutische zusammensetzung umfassend leflunomid |
| KR102101987B1 (ko) | 2013-10-31 | 2020-04-20 | 리제너론 파마슈티칼스 인코포레이티드 | 중화 항체를 검출하기 위한 경합 리간드 결합 분석 |
| WO2015077582A1 (en) * | 2013-11-22 | 2015-05-28 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| PT3071230T (pt) * | 2013-11-22 | 2020-06-26 | Regeneron Pharma | Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas |
| JP7101479B2 (ja) * | 2014-09-16 | 2022-07-15 | サノフィ・バイオテクノロジー | 関節リウマチ患者の健康に関連した生活の質を改善するための組成物 |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| MX2018005589A (es) | 2015-11-03 | 2018-11-09 | Regeneron Pharma | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. |
| KR101895950B1 (ko) * | 2015-12-18 | 2018-09-06 | (주)한국비엠아이 | 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법 |
| JP7166925B2 (ja) * | 2016-03-07 | 2022-11-08 | サノフィ・バイオテクノロジー | 関節リウマチを処置するための組成物及び方法 |
| EP3216461A1 (en) * | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| CN107456455B (zh) * | 2016-06-06 | 2021-09-24 | 海南先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| BR112019006689A2 (pt) | 2016-10-25 | 2019-06-25 | Regeneron Pharma | métodos e sistemas para análise de dados de cromatografia |
| US12042538B2 (en) | 2017-09-19 | 2024-07-23 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| WO2019118187A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Devices and systems for chromatography column bed support management and related methods |
| WO2019136221A1 (en) * | 2018-01-05 | 2019-07-11 | Attillaps Holdings | Treating autoimmune disorders with chloroquine and/or hydroxychloroquine |
| CN108597083A (zh) * | 2018-04-28 | 2018-09-28 | 江苏食品药品职业技术学院 | 一种酒店旅游自助服务系统 |
| TWI814812B (zh) | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
| EA202190056A1 (ru) * | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| CN109013990A (zh) * | 2018-08-04 | 2018-12-18 | 安徽盛美金属科技有限公司 | 一种加热铝合金锻压件坯料的装置 |
| BR112021003206A2 (pt) | 2018-08-29 | 2021-05-25 | Regeneron Pharmaceuticals, Inc. | métodos e composições para tratar indivíduos com artrite reumatoide |
| CN109858649A (zh) * | 2019-01-04 | 2019-06-07 | 珠海格力电器股份有限公司 | 预订酒店方法和装置、酒店管理方法和装置 |
| TWI860325B (zh) | 2019-01-31 | 2024-11-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| AU2020261431A1 (en) | 2019-04-24 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | Methods of diagnosis and treatment of rheumatoid arthritis |
| JP2022534794A (ja) | 2019-06-04 | 2022-08-03 | サノフィ・バイオテクノロジー | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 |
| KR102453140B1 (ko) | 2021-09-07 | 2022-10-11 | 배호진 | 블록체인을 이용한 후원자 보상 방법 및 장치 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| JP2998976B2 (ja) | 1989-07-20 | 2000-01-17 | 忠三 岸本 | ヒトインタ―ロイキン―６レセプターに対する抗体 |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| EP0783893B1 (en) | 1994-10-07 | 2012-04-04 | Chugai Seiyaku Kabushiki Kaisha | Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient |
| CA2203182C (en) | 1994-10-21 | 2009-11-24 | Asao Katsume | Remedy for diseases caused by il-6 production |
| ATE214602T1 (de) | 1994-12-29 | 2002-04-15 | Chugai Pharmaceutical Co Ltd | Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten |
| EP0811384B1 (en) | 1995-02-13 | 2006-06-21 | Chugai Seiyaku Kabushiki Kaisha | Muscle protein decomposition inhibitor containing il-6 receptor antibody |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| AU3276297A (en) | 1996-06-27 | 1998-01-14 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| PT1004315E (pt) | 1997-08-15 | 2008-07-09 | Chugai Pharmaceutical Co Ltd | Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico |
| ES2299241T3 (es) | 1998-03-17 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6. |
| EP1108435B1 (en) | 1998-08-24 | 2007-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| ATE316531T1 (de) | 1999-10-07 | 2006-02-15 | Lilly Co Eli | Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1 |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| US7320792B2 (en) | 2000-10-25 | 2008-01-22 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
| AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| CN100374457C (zh) | 2001-11-14 | 2008-03-12 | 森托科尔公司 | 抗il-6抗体、组合物、方法和用途 |
| DE60334678D1 (de) | 2002-02-14 | 2010-12-09 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende pharmazeutische lösungen |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| MXPA05010778A (es) | 2003-04-09 | 2005-12-12 | Genentech Inc | Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa. |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| WO2005028514A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg. | Use of a compound for reducing the biological effectiveness of il-6 |
| DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| ES2341461T5 (es) | 2004-02-11 | 2014-10-29 | Warner-Lambert Company Llc | Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6 |
| EA014226B1 (ru) | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| EP1810980A1 (en) | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
| EP1828250A2 (en) | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
| RU2008118166A (ru) | 2005-11-22 | 2009-12-27 | Вайет (Us) | Составы, содержащие гибридные белки, включающие иммуноглобулин |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| PL2374818T3 (pl) * | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| KR20090021298A (ko) | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-ｅｇｆｒ 항체의 동결건조 제제 |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| JP2008189637A (ja) | 2007-02-08 | 2008-08-21 | Snow Brand Milk Prod Co Ltd | 自己免疫疾患予防剤 |
| CA2688275A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| AU2008304756B8 (en) | 2007-09-26 | 2015-02-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 receptor antibody |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AR075908A1 (es) | 2009-03-19 | 2011-05-04 | Chugai Pharmaceutical Co Ltd | Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo. |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US20130053751A1 (en) | 2011-08-31 | 2013-02-28 | Frank Holtham | Needle with an antiseptic swab |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| US20150077582A1 (en) | 2013-09-13 | 2015-03-19 | Texas Instruments Incorporated | Method and system for adapting a device for enhancement of images |
| WO2015077582A1 (en) | 2013-11-22 | 2015-05-28 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
-
2012
- 2012-10-09 TW TW101137198A patent/TWI589299B/zh active
- 2012-10-10 JP JP2014535044A patent/JP6122018B2/ja active Active
- 2012-10-10 CA CA2851751A patent/CA2851751A1/en active Pending
- 2012-10-10 HU HUE12769684A patent/HUE036561T2/hu unknown
- 2012-10-10 MX MX2017016768A patent/MX388710B/es unknown
- 2012-10-10 EP EP12769684.7A patent/EP2766039B1/en active Active
- 2012-10-10 SG SG10201607215SA patent/SG10201607215SA/en unknown
- 2012-10-10 KR KR1020227007526A patent/KR20220035272A/ko not_active Ceased
- 2012-10-10 DK DK12769684.7T patent/DK2766039T3/en active
- 2012-10-10 SI SI201231228T patent/SI2766039T1/en unknown
- 2012-10-10 CN CN201280060133.7A patent/CN104105505A/zh active Pending
- 2012-10-10 RU RU2014118741A patent/RU2664697C2/ru active
- 2012-10-10 CN CN201810179358.3A patent/CN108310376A/zh active Pending
- 2012-10-10 KR KR1020147012534A patent/KR20140123474A/ko not_active Ceased
- 2012-10-10 SG SG10201807042YA patent/SG10201807042YA/en unknown
- 2012-10-10 PH PH1/2014/500784A patent/PH12014500784B1/en unknown
- 2012-10-10 BR BR112014008764A patent/BR112014008764A8/pt not_active Application Discontinuation
- 2012-10-10 PL PL12769684T patent/PL2766039T3/pl unknown
- 2012-10-10 NO NO12769684A patent/NO2766039T3/no unknown
- 2012-10-10 MY MYPI2014001045A patent/MY177212A/en unknown
- 2012-10-10 AR ARP120103770A patent/AR088289A1/es unknown
- 2012-10-10 AU AU2012323062A patent/AU2012323062B2/en active Active
- 2012-10-10 WO PCT/EP2012/070052 patent/WO2013053751A1/en not_active Ceased
- 2012-10-10 MX MX2014004398A patent/MX353126B/es active IP Right Grant
- 2012-10-10 RS RS20180191A patent/RS56973B1/sr unknown
- 2012-10-10 TR TR2018/02387T patent/TR201802387T4/tr unknown
- 2012-10-10 PT PT127696847T patent/PT2766039T/pt unknown
- 2012-10-10 LT LTEP12769684.7T patent/LT2766039T/lt unknown
- 2012-10-10 US US14/350,973 patent/US10927435B2/en active Active
- 2012-10-10 KR KR1020197002611A patent/KR20190014117A/ko not_active Ceased
- 2012-10-10 SG SG11201401373RA patent/SG11201401373RA/en unknown
- 2012-10-10 ES ES12769684.7T patent/ES2660112T3/es active Active
- 2012-10-11 UY UY0001034387A patent/UY34387A/es not_active Application Discontinuation
-
2014
- 2014-04-08 IL IL232001A patent/IL232001A0/en active IP Right Grant
- 2014-04-10 MX MX2021015309A patent/MX2021015309A/es unknown
- 2014-04-11 CL CL2014000926A patent/CL2014000926A1/es unknown
- 2014-05-01 MA MA36969A patent/MA35620B1/fr unknown
- 2014-05-09 CO CO14099490A patent/CO6950482A2/es unknown
-
2017
- 2017-03-29 JP JP2017064130A patent/JP6336171B2/ja active Active
-
2018
- 2018-04-27 JP JP2018086193A patent/JP6983717B2/ja active Active
-
2020
- 2020-05-21 JP JP2020088567A patent/JP7025477B2/ja active Active
- 2020-12-24 US US17/133,870 patent/US20210230719A1/en active Pending
-
2024
- 2024-03-14 JP JP2024039618A patent/JP2024069453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530226A5 (OSRAM) | ||
| RU2014118741A (ru) | Композиции для лечения ревматоидного артрита и способы их применения | |
| JP2024069453A5 (OSRAM) | ||
| Rudwaleit et al. | Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study | |
| Behrens et al. | MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | |
| JP2015505564A5 (OSRAM) | ||
| Perdriger | Infliximab in the treatment of rheumatoid arthritis | |
| HRP20251099T1 (hr) | Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju | |
| RU2019140356A (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений | |
| JP2017079785A5 (OSRAM) | ||
| JP2022033891A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| JP2015529225A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| MA38406A1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| JP2016538277A5 (OSRAM) | ||
| JP2016539125A5 (OSRAM) | ||
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| RU2011111391A (ru) | Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r | |
| EP4434540A3 (en) | Humanized anti-il-1r3 antibodies | |
| JP2019528285A5 (OSRAM) | ||
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| JP2018535961A5 (OSRAM) | ||
| BR112014014824A2 (pt) | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos | |
| JP2017520562A5 (OSRAM) |